Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
| ▸ | STK25 | O00506 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16682166 | 0.99 | CYP2D6 (0.47) | CYP2D6GRM4MEN1KMT2AALOX15 | |
| SCHEMBL16675918 | 0.87 | GRM4 (0.43) | CYP2D6GRM4MEN1KMT2AALDH1A1 | |
| SCHEMBL16675913 | 0.86 | GRM4 (0.42) | CYP2D6GRM4MEN1KMT2ASLC6A9 | |
| SCHEMBL18556916 | 0.85 | CYP2D6 (0.46) | CYP2D6GRM4ALOX15CRHR1SLC6A9 | |
| SCHEMBL21093187 | 0.82 | CYP2D6 (0.50) | CYP2D6GRM4ALOX15CRHR1IDO1 | |
| SCHEMBL16860011 | 0.81 | CYP2D6 (0.54) | CYP2D6MEN1KMT2AALOX15SLC6A9 | |
| SCHEMBL16811839 | 0.81 | CYP2D6 (0.54) | CYP2D6MEN1KMT2AALOX15SLC6A9 | |
| SCHEMBL18556908 | 0.81 | CYP2D6 (0.44) | CYP2D6GRM4ALOX15CRHR1SLC6A9 | |
| SCHEMBL16682165 | 0.80 | CYP2D6 (0.46) | CYP2D6GRM4ALOX15CRHR1IDO1 | |
| SCHEMBL18119926 | 0.80 | CYP2D6 (0.46) | CYP2D6GRM4ALOX15XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | CYP2D6 3177/4885GRM4 1007/4885MEN1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.